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1. INTRODUCTION {#ags312180-sec-0001}
===============

Gastrointestinal (GI) cancers are the most common human tumor worldwide, and the incidence and mortality are increasing every year.[1](#ags312180-bib-0001){ref-type="ref"} Several treatment strategies have been developed for GI cancers, including surgery, chemotherapy, radiotherapy, and molecularly targeted therapy. However, the overall survival (OS) of patients with GI cancer remains poor. Novel approaches to the treatment of GI cancer are thus needed.[2](#ags312180-bib-0002){ref-type="ref"}

Immunotherapy is a novel treatment strategy that is emerging as an effective and promising treatment option against several types of cancer.[3](#ags312180-bib-0003){ref-type="ref"} The first immunological treatments were carried out by Coley using a bacterial immunotoxin to patients with malignancy in 1891.[4](#ags312180-bib-0004){ref-type="ref"} The first notion of a role of immunity in cancer was postulated in 1909 by Smith,[5](#ags312180-bib-0005){ref-type="ref"} speculating that the immune system could repress the growth of carcinomas by recognizing tumor cells as foreign. In 1970, the concept of immunological surveillance was presented by Burnet,[6](#ags312180-bib-0006){ref-type="ref"} and an antigen recognized by cytolytic T lymphocytes on a human melanoma was finally reported by van der Bruggen et al.[7](#ags312180-bib-0007){ref-type="ref"}

Progress in this field is largely attributable to the identification of new immune‐based targets, based on continued advances in the understanding of tumor immunology and the tumor microenvironment.[8](#ags312180-bib-0008){ref-type="ref"} Many types of immunomodulatory therapies have been demonstrated in the treatment of GI cancers, including non‐specific biological response modifiers (OK432,[9](#ags312180-bib-0009){ref-type="ref"} lentinan,[10](#ags312180-bib-0010){ref-type="ref"} PSK[11](#ags312180-bib-0011){ref-type="ref"}), interleukin (IL)‐2‐activated lymphocytes,[12](#ags312180-bib-0012){ref-type="ref"} tumor‐specific reactive CD8^+^ T‐lymphocyte transfer,[13](#ags312180-bib-0013){ref-type="ref"} dendritic cell (DC) vaccines,[14](#ags312180-bib-0014){ref-type="ref"}, [15](#ags312180-bib-0015){ref-type="ref"} and tumor‐associated antigen (TAA)‐derived peptides.[16](#ags312180-bib-0016){ref-type="ref"}, [17](#ags312180-bib-0017){ref-type="ref"}, [18](#ags312180-bib-0018){ref-type="ref"}, [19](#ags312180-bib-0019){ref-type="ref"} These immunotherapies have shown a certain degree of efficacy, but not durable objective responses.[20](#ags312180-bib-0020){ref-type="ref"} Confidence in the efficacy of immunotherapies was given a boost with the advent of immune checkpoint inhibitors, which was selected as a "Breakthrough of the Year 2013" by *Science*.[21](#ags312180-bib-0021){ref-type="ref"} Immunotherapy is now becoming mainstream as a treatment for GI cancer.

In the present study, we review immunotherapies for GI malignancies, including immune cell transfer therapy, peptide vaccine, immune checkpoint inhibitors, and combination immunotherapy beyond immune checkpoint inhibitors, by clarifying suppressive immune biomarkers surrounding the tumor microenvironment.

2. IMMUNOTHERAPY AGAINST GI CANCERS {#ags312180-sec-0002}
===================================

2.1. Adoptive T‐cell transfer {#ags312180-sec-0003}
-----------------------------

The concept of adoptive immunotherapy (AIT) for cancer treatment was presented by Mule et al[22](#ags312180-bib-0022){ref-type="ref"} in the form of IL‐2 generated lymphokine‐activated killer (LAK) cells combined with repeated injections of recombinant IL‐2 (Table [1](#ags312180-tbl-0001){ref-type="table"}). Although LAK cells are non‐specific killer cells that were considered effective against various types of tumor, the efficacy of LAK cells combined with high‐dose IL‐2 proved limited against metastatic GI cancer. The objective response rate (ORR) including complete response (CR) or partial response (PR) for colorectal cancer (CRC) was 11% (3 of 27 patients), and 0% (0/1) for esophageal cancer. Furthermore, severe toxicities were observed as a result of high‐dose IL‐2, which induces a vascular permeability leak that leads to fluid retention and interstitial edema, and results in circulatory failure, lung edema, and renal dysfunction. Hence, they made the shift to tumor‐infiltrating lymphocytes (TIL), which are specific to tumor antigens and appear to offer far greater therapeutic potency than LAK cells.[28](#ags312180-bib-0028){ref-type="ref"}

###### 

Previous studies on gastrointestinal cancers discussed in the present review

  Tumor type       Target             Key drug and study design                 Treatment line   Phase   Allocation               Sample size   Clinical efficacy                                         irAE                                                                                                         Reference
  ---------------- ------------------ ----------------------------------------- ---------------- ------- ------------------------ ------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ -------------------------------------------
  CRC              Non‐specific       LAK with IL‐2                             Late             Pilot   Review in an institute   27            3 PR of 27 (11%)                                          SAE as a result of high‐dose IL‐2: fluid retention, circulatory failure, lung edema, and renal dysfunction   [22](#ags312180-bib-0022){ref-type="ref"}
  HCC              Non‐specific       Activated killer cells                    Adjuvant         II      Randomized               150           Longer DFS (*P* = .01) and DSS (*P* = .04) than control   No severe irAE                                                                                               [23](#ags312180-bib-0023){ref-type="ref"}
  Liver tumor^a^   Autologous tumor   CTL, HAI                                  Late             Pilot   Retrospective            15            2 CR and 3 PR of 15 (33%)                                 No severe irAE                                                                                               [24](#ags312180-bib-0024){ref-type="ref"}
  PDAC             MUC1               MUC1‐CTL and gemcitabine                  Adjuvant         Pilot   Retrospective            21            DFS, 15.8 M, OS 24.7 M (median)                           No severe irAE                                                                                               [25](#ags312180-bib-0025){ref-type="ref"}
  PDAC             MUC1               MUC1‐CTL, MUC1‐DC, and gemcitabine        1st              Pilot   Retrospective            42            MST, 13.9 M; 1 CR (2.4%), 3 PR (7.1%) and 22 SD (52.4%)   No severe irAE                                                                                               [15](#ags312180-bib-0015){ref-type="ref"}
  HCC              HSP70              HSP70‐DC                                  Late             I       Dose escalation          12            2 CR (17%), 5 SD                                          Grade 3 liver abscess                                                                                        [14](#ags312180-bib-0014){ref-type="ref"}
  CRC              Oncoantigens       Peptide cocktail with IFA                 Late             I       Dose escalation          18            MST, 13.5 M; 1 CR (6%), 6 SD (33%)                        No severe irAE                                                                                               [26](#ags312180-bib-0026){ref-type="ref"}
  CRC              Oncoantigens       FOLFOX + peptide cocktail with IFA        1st              II      One arm, HLA‐blind       96            ORR and OS did not differ from control group              Grade 5 IP, 2 in study group, 1 in control group                                                             [17](#ags312180-bib-0017){ref-type="ref"}
  PDAC             Oncoantigens       Gemcitabine + peptide cocktail with IFA   Adjuvant         II      One arm                  30            Median DFS, 15.8 M                                        No severe irAE                                                                                               [18](#ags312180-bib-0018){ref-type="ref"}
  HCC              GPC3               GPC3 peptide with IFA                     Adjuvant         II      One arm                  41            Recurrence rate, 28.6% (1 year), 39.4% (2 years)          No severe irAE                                                                                               [27](#ags312180-bib-0027){ref-type="ref"}
  CRC              Tumor specific     TSA with various adjuvants                Late             I/II    Review                   527           1 CR and 4 PR (ORR, 0.9%)                                 Not evaluated                                                                                                [20](#ags312180-bib-0020){ref-type="ref"}

Liver tumor^a^: HCC 13 patients, CRC 2 patients.

CR, complete response; CRC, colorectal cancer; CTL, cytotoxic T cell; DFS, disease‐free survival; DSS, disease‐specific survival; GPC3, glypican‐3; HAI, hepatic arterial infusion; HCC, hepatocellular carcinoma; HLA, human leukocyte antigen; HSP, heat‐shock protein; HSP70‐DC, dendritic cells transfected with HSP70 mRNA; IFA, incomplete Freund\'s adjuvant; IL‐2, interleukin‐2; IP, interstitial pneumonia; irAE, immune‐related adverse effects; LAK, lymphokine‐activated killer cells; M, month; MST, median survival time; MUC1‐DC, dendritic cells transfected with MUC1 mRNA; ORR, objective response rate; OS, overall survival; PDAC, pancreatic ductal adenocarcinoma; PR, partial response; SAE, severe adverse event; SD, stable disease; TSA, tumor‐specific antigen.

John Wiley & Sons, Ltd

Takayama et al conducted a randomized study to evaluate the efficacy of autologous lymphocytes activated in vitro with recombinant IL‐2 and solid‐phase antibody to CD3 as adjuvant therapy for curatively resected HCC. A total of 150 patients who had undergone curative resection for HCC were assigned to receive either AIT (n = 76) or no adjuvant treatment (n = 74). The immunotherapy group showed significantly longer DFS (*P* = .01) and disease‐specific survival (*P* = .04) than the control group. No patients experienced grade 3 or 4 adverse events.[23](#ags312180-bib-0023){ref-type="ref"} These results suggested that transfer of non‐specific‐activated killer cells might be effective in preventing the intrahepatic recurrence of cancer.

The next advance was antigen‐specific cytotoxic T lymphocytes (CTL) for the management of effector cells as treatment.[24](#ags312180-bib-0024){ref-type="ref"}

In Japan, Aruga et al reported autologous tumor‐specific CTL, induced from peripheral blood mononuclear cells (PBMC) cultured with autologous tumor cells. These CTL were injected through the hepatic artery into patients with unresectable liver tumors. Among 15 treated patients (13 with hepatocellular carcinoma \[HCC\] and 2 with metastatic liver cancer), two CR, three PR, and four minor responses were observed without any severe treatment‐associated systemic adverse events.[29](#ags312180-bib-0029){ref-type="ref"}

We have assessed the efficacy of CTL against pancreatic ductal adenocarcinoma (PDAC). Patients with curatively resected PDAC received AIT with CTL stimulated using MUC1‐expressing human cell lines (MUC1‐CTL), and the results indicated that MUC1‐CTL might prevent liver metastasis.[30](#ags312180-bib-0030){ref-type="ref"} For the next step, combination therapy using MUC1‐CTL and gemcitabine was carried out. A total of 43 patients who underwent radical pancreatectomy received treatment with MUC1‐CTL and gemcitabine after surgery. MUC1‐CTL were induced and given i.v. three times, and gemcitabine was given according to the standard regimen for 6 months. No severe treatment‐associated systemic adverse events were encountered in the 43 treated patients. In the adequate treatment group (n = 21) in which the relative dose intensity of gemcitabine was ≥50% and ≥2 MUC1‐CTL treatments were provided, disease‐free survival (DFS) was 15.8 months, and OS was 24.7 months. Liver metastasis was found in seven patients only (33%), and local recurrence occurred in four patients (19%). Combination therapy with AIT and GEM might prevent liver metastasis and local recurrence.[25](#ags312180-bib-0025){ref-type="ref"}

As described above, adoptive immunotherapies have shown a certain degree of efficacy (Table [1](#ags312180-tbl-0001){ref-type="table"}). To obtain more effective arms, revolutions in technologies are needed; these include expanding neoantigen recognized TIL or genetically engineered T cells such as T‐cell receptor (TCR) T cells and chimeric antigen receptor (CAR) T cells.[31](#ags312180-bib-0031){ref-type="ref"}

So‐called CAR‐T therapy was also selected as a "Breakthrough of the Year 2013" by *Science*.[21](#ags312180-bib-0021){ref-type="ref"} CAR‐modified T cells (CAR‐T) targeting CD19 showed durable effects against leukemia, achieving complete remission.[32](#ags312180-bib-0032){ref-type="ref"} For gastrointestinal tumor, CAR‐T therapies remain experimental.[33](#ags312180-bib-0033){ref-type="ref"} In clinical studies of CRC[34](#ags312180-bib-0034){ref-type="ref"} and biliary tract and pancreatic cancers,[35](#ags312180-bib-0035){ref-type="ref"} some promising results have been reported in the form of PR and long‐term stable disease without uncontrollable toxicities. The novel next‐generation CAR‐T therapy was reported by Adachi et al.[36](#ags312180-bib-0036){ref-type="ref"} They engineered CAR‐T cells to express IL‐7 and chemokine (C‐C motif) ligand 19 (CCL19) (7 × 19 CAR‐T cells), as these factors are essential for the maintenance of T‐cell zones in lymphoid organs. In mice, 7 × 19 CAR‐T cells achieved complete regression of pre‐established solid tumors with anti‐tumor activity superior to that of conventional CAR‐T cells. Histopathological analyses showed increased infiltration of DC and T cells into tumor tissues following 7 × 19 CAR‐T‐cell therapy,[36](#ags312180-bib-0036){ref-type="ref"} which might be adapted against gastrointestinal cancers in the near future.

2.2. Dendritic cell vaccines {#ags312180-sec-0004}
----------------------------

Dendritic cells are antigen‐presenting cells specialized for the induction of a primary T‐cell response. A clinical pilot study reported generation of DC in the presence of granulocyte‐macrophage colony‐stimulating factor and IL‐4. These cells were pulsed with tumor lysate or a cocktail of TAA‐derived peptides. This method to induce DC has been used as a standard worldwide.[37](#ags312180-bib-0037){ref-type="ref"} The study analyzed 16 patients with advanced melanoma, and objective responses were evident in five of these 16 evaluated patients.

For patients with PDAC, the clinical efficacy of immunotherapy using both DC transfected with MUC1 mRNA (MUC1‐DC) and MUC1‐CTL was evaluated in a pilot study with gemcitabine. Forty‐two patients with unresectable or recurrent PDAC were enrolled, and median survival time was 13.9 months, with a 1‐year survival rate of 51.1%. Of the 42 patients, one patient achieved CR (2.4%), three patients had PR (7.1%), and 22 patients had stable disease (SD) (52.4%). The disease control rate (DCR) was thus 61.9%. No severe toxicities were associated with cell transfer. MUC1‐DC and MUC1‐CTL plus gemcitabine might offer an effective treatment for PDAC.[15](#ags312180-bib-0015){ref-type="ref"}

Another target of DC therapy is HCC. A phase I trial was conducted on the basis of a previous basic study that reported overexpression of heat‐shock protein (HSP) 70 in HCC using proteomic profiling and immunohistochemical staining.[38](#ags312180-bib-0038){ref-type="ref"} DC transfected with HSP70 mRNA (HSP70‐DC) by electroporation were injected intradermally. Patients were treated three times every 3 weeks, and the number of HSP70‐DC injected was dose‐escalated in a three‐patient method, from 1 × 10^7^ to 2 × 10^7^, and finally to 3 × 10^7^. No adverse effects at grade III/IV were observed, except for one case of grade III liver abscess at the 3 × 10^7^ dose, and three patients were therefore added to confirm the safety of the 3 × 10^7^ dosage. CR without any recurrence was achieved in two patients (for at least 44 and 33 months) and SD in five patients. That study indicated that HSP70‐DC therapy is both safe and effective in patients with HCC.[14](#ags312180-bib-0014){ref-type="ref"}

DC vaccines might gain a place in novel combination immunotherapy.

2.3. Peptide vaccines {#ags312180-sec-0005}
---------------------

Since the first clinical trial of a melanoma antigen gene‐1‐derived peptide‐based vaccine was reported in 1995,[39](#ags312180-bib-0039){ref-type="ref"} various types of next‐generation peptide vaccine are currently under development.[16](#ags312180-bib-0016){ref-type="ref"} Here, we present some successful reports from among these numerous studies.

We conducted phase I and phase II trials using HLA‐A\*24:02‐restricted peptides, three derived from oncoantigens and two from vascular endothelial growth factor receptors (VEGFR) against CRC. In the phase I study, 18 HLA‐A\*2402‐positive CRC patients for whom standard therapy had failed were enrolled, and 0.5 mg, 1.0 mg, or 3.0 mg each of the peptides was mixed with incomplete Freund\'s adjuvant (IFA) and then s.c. injected. Vaccine treatment was well tolerated without any severe treatment‐associated systemic adverse events.[26](#ags312180-bib-0026){ref-type="ref"} One patient who achieved CR remains alive without recurrence more than 10 years after the initial vaccinations, and six patients showed stable disease for 4‐7 months. Median overall survival time (MST) was 13.5 months.

The phase II study was conducted to evaluate the efficacy of this approach in combination with oxaliplatin‐based chemotherapy as a first‐line therapy. Ninety‐six chemotherapy‐naïve CRC patients with measurable metastatic or unresectable lesions were enrolled under masking of HLA‐A status. Although ORR and OS did not differ between the HLA‐A\*2402‐matched and unmatched groups, a significantly delayed response was observed in the subgroup with a neutrophil‐to‐lymphocyte ratio (NLR) \<3.0 according to the Harrington‐Fleming method. Although the incidences of serious adverse events (SAE) were broadly similar between groups, that of neutropenia was relatively higher in the HLA‐A\*2402‐matched group than in the unmatched group. Interstitial pneumonia that led to death was observed in two cases in the HLA‐matched group and in one case in the HLA‐unmatched group.[17](#ags312180-bib-0017){ref-type="ref"}

In the adjuvant setting, Miyazawa et al reported that 30 patients with resected PDAC were treated using a peptide cocktail vaccine containing epitope peptides derived from KIF20A, VEGFR1, and VEGFR2 combined with gemcitabine as a single‐arm multicenter phase II study. No serious (more than grade 3) immune‐related adverse events (irAE) were encountered. Median DFS was 15.8 months. This study also conducted comparisons with 15 patients treated using gemcitabine alone as a prospective control group that did not meet eligibility criteria as a result of HLA‐A type only, for whom the median DFS was 12.0 months. No significant difference was seen between the two groups (*P* = .504). Significant differences in DFS were apparent between patients with and without KIF20A‐specific CTL responses (*P* = .027), and between patients with and without KIF20A expression (*P* = .014). In addition, all four patients who underwent R0 resection with KIF20A expression showed no recurrence with KIF20A‐specific CTL responses.[18](#ags312180-bib-0018){ref-type="ref"}

Sawada et al identified in glypican‐3 (GPC‐3) an HLA‐A\*24, HLA‐A\*02 restriction peptide with extreme cancer specificity. In a phase I study, they reported safety, and immunological and clinical responses.[40](#ags312180-bib-0040){ref-type="ref"} A subsequent trial showed a durable effect against giant HCC, although the patients died from circulatory failure as a result of tumor thrombus, which occupied most of the right atrium.[41](#ags312180-bib-0041){ref-type="ref"} In the next phase II study of GPC3 peptide vaccine as an adjuvant therapy for HCC, no significant difference in recurrence rate was found between 35 patients treated with surgery plus vaccination and 33 patients who underwent surgery alone (28.6% vs 54.3% at 1 year and 39.4% vs 54.5% at 2 years, respectively; *P* = .346, .983). In a subgroup analysis, 25 patients treated with vaccination showed GPC3‐positive tumors and a significantly lower recurrence rate compared to that in the 21 GPC3‐positive patients who received surgery alone (24% vs 48% at 1 year and 52.4% vs 61.9% at 2 years, respectively; *P* = .047, .387). GPC3 peptide vaccine improved the 1‐year recurrence rate in patients with GPC3‐positive tumors.[27](#ags312180-bib-0027){ref-type="ref"}

Although tumor‐associated antigen‐derived peptide vaccines have been shown to provide effective induction of antigen‐specific immunity, the clinical efficacy has not proven durable (Table [1](#ags312180-tbl-0001){ref-type="table"}). As a result, no peptides are covered by the National Health Insurance. Pooled results of clinical trials show a very weak clinical response rate of \<1% for the active specific immunization procedures currently available for advanced CRC.[20](#ags312180-bib-0020){ref-type="ref"} Rosenberg et al reported that the objective response rate was low (2.6%) in their cancer vaccine trials of 440 patients, even though the main target was melanoma, which is highly immunogenic.[42](#ags312180-bib-0042){ref-type="ref"}

Combination immunotherapy appears needed for peptide vaccinations such as immune checkpoint inhibitors,[43](#ags312180-bib-0043){ref-type="ref"} novel immune adjuvants,[44](#ags312180-bib-0044){ref-type="ref"} COX‐2 inhibitors,[45](#ags312180-bib-0045){ref-type="ref"} and anti‐epidermal growth factor receptor (EGFR) antibodies.[46](#ags312180-bib-0046){ref-type="ref"} Such novel approaches are described in detail in later sections.

Neoantigens, a class of HLA‐bound peptides that arise from tumor‐specific mutations, are highly immunogenic because they are not present in normal tissues and hence bypass central thymic tolerance. Ott et al demonstrated the feasibility, safety, and immunogenicity of a vaccine targeting up to 20 predicted personal tumor neoantigens using machine learning approaches to reliably predict those mutated peptides with high‐affinity binding of autologous HLA molecules. Of six vaccinated patients, four showed no recurrence at 25 months after vaccination, whereas two with recurrent disease were subsequently treated with anti‐programmed cell death protein 1 (PD‐1) therapy and achieved CR, with expansion of the repertoire of neoantigen‐specific T cells. These data provide a strong rationale for further development of this approach alone and in combination with checkpoint blockade or other immunotherapies.[47](#ags312180-bib-0047){ref-type="ref"} Simultaneously, the first in‐human application of this concept was carried out in melanoma using an RNA‐based poly‐neo‐epitope approach comprising computational prediction of neo‐epitopes, and design and manufacturing of a vaccine unique to each patient. All patients developed T‐cell responses against multiple vaccine neo‐epitopes at up to high single‐digit percentages. Cumulative rate of metastatic events was significantly reduced after the start of vaccination, resulting in sustained progression‐free survival (PFS). Two of the five patients with metastatic disease experienced vaccine‐related objective responses. A third patient developed CR to vaccination in combination with PD‐1 blockade therapy.[48](#ags312180-bib-0048){ref-type="ref"} Although these reports involved melanoma, this strategy holds promise for the treatment of gastrointestinal cancers.

3. IMMUNE CHECKPOINT INHIBITORS {#ags312180-sec-0006}
===============================

Recently, the effectiveness of immunotherapy targeting immune checkpoints in the treatment of numerous forms of cancer has been studied. In 2011, the Food and Drug Administration in the USA approved ipilimumab, an anti‐cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA‐4) treatment for metastatic melanoma. In 2012, Topalian et al[49](#ags312180-bib-0049){ref-type="ref"} reported results for PD‐1 therapy in nearly 300 people, and an update was provided in 2013.[50](#ags312180-bib-0050){ref-type="ref"} Tumors shrunk by about half or more in 31% of those with melanoma, in 29% with kidney cancer, and in 17% with lung cancer. Immune checkpoint inhibitors have also been applied to gastrointestinal cancers (Tables [2](#ags312180-tbl-0002){ref-type="table"}, [3](#ags312180-tbl-0003){ref-type="table"}, [4](#ags312180-tbl-0004){ref-type="table"}).

###### 

Published studies of immune checkpoint inhibitors for gastrointestinal cancers discussed in the present review

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tumor type             Target   Key drug and trial identifier   Treatment line   Phase   Allocation                      Sample size        Clinical efficacy                                                      irAE                                                                                                                          Reference
  ---------------------- -------- ------------------------------- ---------------- ------- ------------------------------- ------------------ ---------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- -------------------------------------------
  ESCC                   PD‐1     Nivolumab,\                     Late             II      Single arm                      64                 ORR, 11 of 64 (17%)                                                    Lung infection (4), dehydration (2), IP (2) of 65No treatment‐related deaths                                                  [51](#ags312180-bib-0051){ref-type="ref"}
                                  ONO‐4538‐07                                                                                                                                                                                                                                                                                                      

  GC or GEJC             PD‐1     Nivolumab,\                     3rd or more      III     Randomized, double‐blind        493 (330 vs 163)   ORR, 30 (11.2%) of 268, 1Y OS: 26.2% (Nivo) vs 10.9% (Place)           Grade 3 or 4 irAE in 34 (10%); irAE led to death in 5 (2%)                                                                    [52](#ags312180-bib-0052){ref-type="ref"}
                                  ATTRACTION‐2                                                                                                                                                                                                                                                                                                     

  PD‐L1 + \              PD‐1     Pembrolizumab,\                 Late             Ib      Single arm                      39                 ORR, 22% (8 of 36)                                                     Grade 3, 2 fatigue, 1 PG, 1 hypothyroidism, 1 PSN; Grade 4, 1 IP No treatment‐related deaths                                  [53](#ags312180-bib-0053){ref-type="ref"}
  GC or GEJC                      KEYNOTE‐012                                                                                                                                                                                                                                                                                                      

  GC or GEJC             PD‐1     Pembrolizumab,\                 3rd or more      II      Single arm                      259                ORR, 15.5% in PD‐L1+ pts, 5.5% in PD‐L1-- pts                          Grade 3‐5 irAE in 43 (16.6%), discontinuation in 2 (LFT, BDS), fatal in 2 (AKI, PE)                                           [54](#ags312180-bib-0054){ref-type="ref"}
                                  KEYNOTE‐059‐Cohort 1                                                                                                                                                                                                                                                                                             

  dMMR/MSI‐H CRC         PD‐1     Pembrolizumab,\                 Late             II      Single arm                      28                 ORR, 40% (4 of 10) for dMMR/MSI‐H CRC, 0% (0 of 18) for pMMR CRC       Grade 3 and 4 irAE, anemia (17%), lymphopenia (20%), diarrhea (5%), BO (7%)                                                   [55](#ags312180-bib-0055){ref-type="ref"}
                                  CT01876511                                                                                                                                                                                                                                                                                                       

  dMMR/MSI‐H tumors^a^   PD‐1     Pembrolizumab,\                 2nd or more      II      Single arm                      86                 ORR, 53%; CR, 21%                                                      irAE were manageable74% had AE (Grade 1 or more), hypothyroidism (21%) managed with THR                                       [56](#ags312180-bib-0056){ref-type="ref"}
                                  CT01876511                                                                                                                                                                                                                                                                                                       

  dMMR/MSI‐H CRC         PD‐1     Nivolumab,\                     2nd or more      II      Single arm                      74                 ORR, 31.1% (23 of 74)                                                  Common grade 3 or 4 irAE, elevation of lipase (6) and amylase (2). No treatment‐related deaths                                [57](#ags312180-bib-0057){ref-type="ref"}
                                  CheckMate 142                                                                                                                                                                                                                                                                                                    

  dMMR/MSI‐H CRC         PD‐1\    Nivolumab + ipilimumab\         2nd or more      II      Single arm                      119                ORR, 55% (65 of 119), 4 CR, 61 PR                                      Grade 3 irAE in 32, AST or ALT (11%), lipase (4%), anemia or colitis (3%), hypothyroidism (1%). No treatment‐related deaths   [58](#ags312180-bib-0058){ref-type="ref"}
                         CTLA‐4   CheckMate 142                                                                                                                                                                                                                                                                                                    

  HCC                    PD‐1     Nivolumab,\                     1st or more      I/II    Dose escalation and expansion   P I, 48\           ORR, 15% (3 CR, 4 PR of 48) in P I, 20% in P II (3 CR, 39 PR of 214)   12 (25%) of 48 had grade 3/4 irAE; 3 (6%) had serious AE (PG, adrenal insufficiency, liver disorder)                          [59](#ags312180-bib-0059){ref-type="ref"}
                                  CheckMate 040                                                                            P II, 214                                                                                                                                                                                                               

  PDAC                   PD‐L1    BMS‐936559,\                    1st or more      I       Dose escalation                 Total, 207\        PDAC, 0 of 14 (0%)                                                     MTD was not reachedirAE, 81 of 207 (39%), included rash, hypothyroidism, hepatitis, diabetes mellitus                         [60](#ags312180-bib-0060){ref-type="ref"}
                                  CT00729664                                                                               PDAC, 16                                                                                                                                                                                                                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

dMMR tumors^a^: 12 different tumor types.

AKI, acute kidney injury; BDS, bile duct stenosis; BO, bowel obstruction; CR, complete response; CRC, colorectal cancer; CTLA‐4, cytotoxic T‐lymphocyte‐associated protein 4; dMMR, defective mismatch repair; ESCC, esophageal squamous cell carcinoma; GC or GEJC, gastric or gastroesophageal junction cancer; HCC, hepatocellular carcinoma; IP, interstitial pneumonia; irAE, immune‐related adverse effect; Late, standard therapy failure; LFT, liver function test; MSI‐H, microsatellite instability‐high; MTD, maximum tolerated dose; Nivo, nivolumab; ORR, objective response rate; PD‐1, programmed cell death 1; PDAC, pancreatic ductal adenocarcinoma; PD‐L1, programmed cell death ligand 1; PE, pleural effusion; PG, pemphigoid; Place, placebo; pMMR, proficient mismatch repair; PR, partial response; PSN, peripheral sensory neuropathy; pts, patients; THR, thyroid hormone replacement.

John Wiley & Sons, Ltd

###### 

Approved immune checkpoint inhibitors for gastrointestinal cancers

  Date        Target   Drug            Tumor type                           Indication                                                                                                        Approval   Reference
  ----------- -------- --------------- ------------------------------------ ----------------------------------------------------------------------------------------------------------------- ---------- -------------------------------------------
  22 Sep 17   PD‐1     Nivolumab       HCC                                  HCC previously treated with sorafenib                                                                             FDA        [59](#ags312180-bib-0059){ref-type="ref"}
  1 Aug 17    PD‐1     Nivolumab       CRC with MSI‐H or dMMR               MSI‐H or dMMR metastatic CRC that has progressed following treatment                                              FDA        [57](#ags312180-bib-0057){ref-type="ref"}
  22 Sep 17   PD‐1     Pembrolizumab   GC or GEJC                           Previously treated patients with recurrent locally advanced or metastatic GC or GEJC whose tumors express PD‐L1   FDA        [54](#ags312180-bib-0054){ref-type="ref"}
  23 May 17   PD‐1     Pembrolizumab   Any solid tumor with dMMR or MSI‐H   First cancer treatment for any solid tumor with dMMR or MSI‐H                                                     FDA        [56](#ags312180-bib-0056){ref-type="ref"}
  28 Sep 17   PD‐1     Nivolumab       GC or GEJC                           Previously treated patients with advanced GC or GEJC                                                              Japan      [52](#ags312180-bib-0052){ref-type="ref"}

CRC, colorectal cancer; dMMR, defective mismatch repair; FDA, Food & Drug Administration; GC or GEJC, gastric or gastroesophageal junction cancer; HCC, hepatocellular carcinoma; MSI‐H, microsatellite instability‐high; PD‐1, programmed cell death 1; PD‐L1, programmed death ligand 1.

John Wiley & Sons, Ltd

###### 

Ongoing studies of immune checkpoint inhibitors

  Tumor type                               Target                                 Key drug                 Trial design (arm)                         Trial identifier      Treatment line   Phase   Allocation   Status                   Sample size   Study start date   Estimated primary completion date
  ---------------------------------------- -------------------------------------- ------------------------ ------------------------------------------ --------------------- ---------------- ------- ------------ ------------------------ ------------- ------------------ -----------------------------------
  dMMR or MSI‐H CRC                        PD‐1                                   Pembrolizumab            Pembrolizumab                              Keynote 177           1st              III     Randomized   Active,                  300           30 Nov 15          15 Aug 19
  Standard 1st‐line therapy for CRC        NCT02563002                            not recruiting                                                                                                                                                                            
  dMMR or MSI‐H CRC                        PD‐1                                   Pembrolizumab            Pembrolizumab                              Keynote 164           2nd or more      II      Single arm   Active,                  124           25 Aug 15          09 Sep 19
  NCT02460198                              not recruiting                                                                                                                                                                                                                   
  GC or GEJC                               PD‐1                                   Nivolumab                Nivolumab + chemotherapy (SOX or CapeOX)   ONO‐4538‐37           1st              III     Randomized   Recruiting               680           Mar 16             Aug 20
  Placebo + chemotherapy (SOX or CapeOX)   NCT02746796                                                                                                                                                                                                                      
  GC or GEJC                               PD‐1, CTLA‐4                           Nivolumab + ipilimumab   Nivolumab + ipilimumab                     CheckMate649          1st              III     Randomized   Recruiting               1349          04 Oct 16          12 Mar 20
  XELOX or FOLFOX                          NCT02872116                                                                                                                                                                                                                      
  Nivolumab + XELOX or FOLFOX                                                                                                                                                                                                                                               
  GC                                       PD‐1                                   Nivolumab                Nivolumab + chemotherapy (S‐1 or CapeOX)   ONO‐4538‐38           adjuvant         III     Randomized   Recruiting               700           Jan 17             Jun 21
  Placebo + chemotherapy (S‐1 or CapeOX)   NCT03006705                                                                                                                                                                                                                      
  GC or GEJC                               PD‐1                                   Pembrolizumab            Pembrolizumab monotherapy                  KEYNOTE‐062           1st              III     Randomized   Active, not recruiting   764           31 Jul 15          05 Feb 19
  Pembrolizumab + cisplatin + 5‐FU         NCT02494583                                                                                                                                                                                                                      
  Placebo + cisplatin + 5‐FU                                                                                                                                                                                                                                                
  GC or GEJC                               PD‐1                                   Pembrolizumab            Pembrolizumab                              KEYNOTE‐063           2nd              III     Randomized   Active, not recruiting   360           16 Feb 17          17 Aug 19
  Paclitaxel                               NCT03019588                                                                                                                                                                                                                      
  GC or GEJC                               PD‐1                                   Pembrolizumab            Pembrolizumab + XP or FP                   KEYNOTE‐585           Neoadjuvant      III     Randomized   Recruiting               860           09 Oct 17          26 Jul 23
  Placebo + XP or FP                       NCT03221426                            Adjuvant                                                                                                                                                                                  
  GC or GEJC                               PD‐L1                                  Avelumab                 Induction phase: FOLFOX or CapeOX          JAVELIN Gastric 100   1st              III     Randomized   Active, not recruiting   499           24 Dec 15          13 Mar 19
  Maintenance phase: avelumab              NCT02625610                                                                                                                                                                                                                      
  Induction phase: FOLFOX or CapeOX                                                                                                                                                                                                                                         
  Maintenance phase: FOLFOX or CapeOX                                                                                                                                                                                                                                       
  ESCC                                     PD‐1                                   Nivolumab                Nivolumab                                  ONO‐4538‐24           2nd              III     Randomized   Active, not recruiting   390           Dec 15             Sep 19
  Docetaxel or paclitaxel                  NCT02569242                                                                                                                                                                                                                      
  ESCC                                     PD‐1                                   Nivolumab + ipilimumab   Nivolumab + ipilimumab                     CheckMate 648         1st              III     Randomized   Recruiting               939           19 Jun 17          25 May 20
  CTLA‐4                                   Nivolumab + cisplatin + fluorouracil   NCT03143153                                                                                                                                                                               
  Cisplatin + fluorouracil                                                                                                                                                                                                                                                  
  ESCC                                     PD‐1                                   Pembrolizumab            Pembrolizumab                              KEYNOTE‐181           2nd              III     Randomized   Recruiting               720           01 Dec 15          25 Sep 19
  Paclitaxel or docetaxel or irinotecan    NCT02564263                                                                                                                                                                                                                      
  EC or EGJC                               PD‐1                                   Pembrolizumab            Pembrolizumab + cisplatin + 5‐FU           KEYNOTE‐590           1st              III     Randomized   Recruiting               700           25 Jul 17          22 Aug 21
  Placebo + cisplatin + 5‐FU               NCT03189719                                                                                                                                                                                                                      
  HCC                                      PD‐1                                   Nivolumab                Nivolumab                                  CheckMate 9DX         Adjuvant         III     Randomized   Recruiting               530           18 Dec 17          17 Apr 22
  Placebo                                  NCT03383458                                                                                                                                                                                                                      
  HCC                                      PD‐1                                   Nivolumab                Nivolumab                                  CheckMate 459         2nd              III     Randomized   Active, not recruiting   726           25 Nov 15          16 Oct 18
  Sorafenib                                NCT02576509                                                                                                                                                                                                                      
  HCC                                      PD‐1                                   Pembrolizumab            Pembrolizumab + BSC                        KEYNOTE‐394           2nd or more      III     Randomized   Recruiting               330           27 Apr 17          23 Dec 19
  Placebo + BSC                            NCT03062358                                                                                                                                                                                                                      
  HCC                                      PD‐1                                   Pembrolizumab            Pembrolizumab + BSC                        KEYNOTE‐240           2nd or more      III     Randomized   Active, not recruiting   408           26 May 16          01 Feb 19
  Placebo + BSC                                                                                                                                                                                                                                                             

BSC, best supportive care; CRC, colorectal cancer; dMMR, defective mismatch repair; EC or EGJC, adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the esophagogastric junction; ESCC, esophageal squamous cell carcinoma; FP, cisplatin + 5‐fluorouracil; GC or GEJC, gastric or gastroesophageal junction cancer; HCC, hepatocellular carcinoma; MSI‐H, microsatellite instability‐high; XP, cisplatin + capecitabine.
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3.1. Esophageal cancer {#ags312180-sec-0007}
----------------------

Compared with other solid tumors, esophageal squamous cell carcinoma (ESCC) has a very high somatic mutation rate.[61](#ags312180-bib-0061){ref-type="ref"}, [62](#ags312180-bib-0062){ref-type="ref"} The high mutation load in esophageal tumors has been associated with the clinical benefit of PD‐1 blockade.[63](#ags312180-bib-0063){ref-type="ref"} Nivolumab is a human monoclonal immunoglobulin (Ig)G4 antibody that seals PD‐1 expressed on activated T cells. This drug was applied to treatment‐refractory esophageal cancer in an open‐label, multicenter, phase II trial (Table [2](#ags312180-tbl-0002){ref-type="table"}). Nivolumab showed promising activity with a manageable safety profile.[51](#ags312180-bib-0051){ref-type="ref"} PD‐1/PD‐L1 blockade alone or in combination with radiotherapy and chemotherapy will be a direction for future research in the treatment of advanced esophageal cancer (Table [4](#ags312180-tbl-0004){ref-type="table"}).

3.2. Gastric cancer {#ags312180-sec-0008}
-------------------

To assess the efficacy and safety of nivolumab in patients with advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC) refractory to, or intolerant of, two or more previous regimens of chemotherapy, a randomized, double‐blind, placebo‐controlled, phase III trial was carried out (Table [2](#ags312180-tbl-0002){ref-type="table"}). In that phase III study, survival benefits indicated that nivolumab might represent a new treatment option for heavily pretreated patients with advanced GC or GEJC. Based on that study, nivolumab was approved in Japan for unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy (Table [3](#ags312180-tbl-0003){ref-type="table"}).[52](#ags312180-bib-0052){ref-type="ref"}

Pembrolizumab uses another developmental strategy to target patients with programmed death ligand 1 (PD‐L1)‐positive advanced gastric cancer. A phase Ib trial designed to assess the safety and activity of pembrolizumab was carried out in patients with PD‐L1‐positive recurrent or metastatic GC or GEJC. Patients received i.v. pembrolizumab at 10 mg/kg once every 2 weeks (Table [2](#ags312180-tbl-0002){ref-type="table"}). Pembrolizumab showed a manageable toxicity profile and promising antitumor activity.[53](#ags312180-bib-0053){ref-type="ref"} The FDA approved pembrolizumab for previously treated patients with recurrent locally advanced or metastatic GC or GEJC whose tumors express PD‐L1. This decision was based on data from a global multicohort trial, KEYNOTE‐059, which indicated a superior response in patients with tumors that expressed PD‐L1 (Tables [2](#ags312180-tbl-0002){ref-type="table"},[3](#ags312180-tbl-0003){ref-type="table"}).[54](#ags312180-bib-0054){ref-type="ref"}

Ongoing trials are investigating various settings and earlier treatment lines for GC or GEJC (Table [4](#ags312180-tbl-0004){ref-type="table"}).

3.3. Colorectal cancer {#ags312180-sec-0009}
----------------------

In early‐phase studies, responses of CRC to PD‐1/PD‐L1 inhibitors were not promising.[60](#ags312180-bib-0060){ref-type="ref"} No objective response was seen in patients treated with PD‐1 inhibitors (0/19)[49](#ags312180-bib-0049){ref-type="ref"} or PD‐L1 inhibitors (0/16). Surprisingly, updated reports have indicated that patients with metastatic CRC who harbored the microsatellite instability‐high (MSI‐H) genotype achieved objective responses after disease progression on an intermittent dosing regimen of PD‐1 inhibitors and finally achieved complete responses.[50](#ags312180-bib-0050){ref-type="ref"} The majority of colorectal cancers are proficient mismatch repair (pMMR) tumors, and approximately 15% show defective mismatch repair (dMMR), which can be measured by either the five‐marker panel with fluorescent multiplex assay[64](#ags312180-bib-0064){ref-type="ref"} or by the lack of DNA mismatch repair proteins.[65](#ags312180-bib-0065){ref-type="ref"} Tumors with dMMR can have MSI‐H and a somatic mutation frequency of more than 10‐ to 100‐fold that of pMMR tumors.[66](#ags312180-bib-0066){ref-type="ref"} Hence, dMMR (MSI‐H) tumor is thought to have the potential to encode "non‐self" immunogenic antigens and predict responsiveness to the immune checkpoint blockade (Tables [2](#ags312180-tbl-0002){ref-type="table"}, [3](#ags312180-tbl-0003){ref-type="table"}, [4](#ags312180-tbl-0004){ref-type="table"}).

Based on this perspective, a phase II study was conducted to evaluate the clinical activity of pembrolizumab, an anti‐PD‐1 immune checkpoint inhibitor, and 32 patients with progressive metastatic carcinoma with or without dMMR were enrolled and received i.v. pembrolizumab. Objective response rates (ORR) were 40% for dMMR colorectal cancers and 0% for pMMR colorectal cancers. Median PFS and OS were not reached in the cohort with dMMR CRC, but were 2.2 months and 5.0 months, respectively, in the cohort with pMMR CRC. Whole‐exome sequencing showed a mean of 1782 somatic mutations per tumor in dMMR tumors, as compared with 73 in pMMR tumors, and high somatic mutation loads were associated with prolonged PFS (*P* = .02). This study showed that patients with dMMR are good candidates for receiving immune checkpoint blockade (Table [2](#ags312180-tbl-0002){ref-type="table"}).[55](#ags312180-bib-0055){ref-type="ref"}

Next, this study was expanded to evaluate the efficacy of PD‐1 blockade in patients with advanced dMMR cancers across 12 different tumor types. Responses were durable with median PFS and OS still not reached. These data support the hypothesis that the large proportion of mutant neoantigens in dMMR cancers make them sensitive to immune checkpoint blockade, regardless of the tissue of origin for the cancer,[56](#ags312180-bib-0056){ref-type="ref"} and the FDA approved the use of pembrolizumab in the treatment of patients with MSI‐H or dMMR (Tables [2](#ags312180-tbl-0002){ref-type="table"}, [3](#ags312180-tbl-0003){ref-type="table"}).

Similar results were obtained from an open‐label, phase II study of nivolumab in patients with dMMR/MSI‐H metastatic CRC. Patients were given nivolumab at 3 mg/kg every 2 weeks until disease progression or unacceptable toxic effects (Table [2](#ags312180-tbl-0002){ref-type="table"}).[57](#ags312180-bib-0057){ref-type="ref"} The FDA approved nivolumab use in the treatment for MSI‐H or dMMR metastatic colorectal cancer that has progressed following treatment (Table [3](#ags312180-tbl-0003){ref-type="table"}). Studies of immune checkpoint inhibitors are ongoing to indicate potential efficacy as first‐line agents (Table [4](#ags312180-tbl-0004){ref-type="table"}).

3.4. Hepatocellular carcinoma {#ags312180-sec-0010}
-----------------------------

The only evidence‐based systemic treatment option is sorafenib, a small‐molecule multikinase inhibitor, for patients with advanced hepatocellular carcinoma (HCC).[67](#ags312180-bib-0067){ref-type="ref"} The presence of tumor‐infiltrating lymphocytes expressing PD‐1 in HCC lesions and their correlation with outcome suggest that immunotherapeutic approaches might be useful in this setting.[68](#ags312180-bib-0068){ref-type="ref"} To assess the safety and efficacy of nivolumab, a phase I/II dose escalation and expansion trial was designed in patients with advanced HCC with or without chronic viral hepatitis. Eligible patients had Child‐Pugh scores of 7 or less (Child‐Pugh A or B7) for the dose‐escalation phase and 6 or less (Child‐Pugh A) for the dose‐expansion phase. Patients with hepatitis B virus (HBV) infection had to be receiving effective antiviral therapy (viral load \<100 IU/mL), but antiviral therapy was not required for patients with hepatitis C virus (HCV) infection. Patients received i.v. nivolumab at 0.1‐10 mg/kg every 2 weeks in the dose‐escalation phase (3 + 3 design). Nivolumab 3 mg/kg was given every 2 weeks in the dose‐expansion phase to patients in four cohorts: sorafenib untreated or intolerant without viral hepatitis; sorafenib failure without viral hepatitis; HCV infected; and HBV infected. A total of 262 eligible patients were treated. During dose escalation, nivolumab showed a manageable safety profile, including acceptable tolerability. Incidence of treatment‐related adverse events did not seem to be associated with dose and no maximum tolerated dose was reached, and nivolumab 3 mg/kg was chosen for dose expansion. Durable objective responses show the potential for nivolumab in the treatment of advanced HCC (Table [2](#ags312180-tbl-0002){ref-type="table"}),[59](#ags312180-bib-0059){ref-type="ref"} and nivolumab received FDA approval for the treatment of hepatocellular carcinoma patients previously treated with sorafenib (Table [3](#ags312180-tbl-0003){ref-type="table"}).

3.5. Pancreatic ductal adenocarcinoma {#ags312180-sec-0011}
-------------------------------------

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies worldwide. Desmoplasia (abundant fibrotic stroma) is a typical feature of PDAC in humans, and stromal activation commonly starts around precancerous lesions. Cancer‐stroma interactions affect tumorigenesis, angiogenesis, therapy resistance and, possibly, the metastatic spread of tumor cells.[69](#ags312180-bib-0069){ref-type="ref"} In fact, no objective response was observed in 14 pancreatic cancer (PC) patients treated with BMS‐936559, an anti‐PD‐L1 antibody (Table [2](#ags312180-tbl-0002){ref-type="table"}).[60](#ags312180-bib-0060){ref-type="ref"} Therefore, targeting the tumor stroma offers a promising new option for the treatment of PDAC. The immunosuppressive environment surrounding PDAC appears to be one of the major obstacles to the development of successful therapies for this fatal disease.[69](#ags312180-bib-0069){ref-type="ref"}

4. COMBINATION IMMUNOTHERAPY BASED ON PRECISION MEDICINE: BEYOND IMMUNE CHECKPOINT INHIBITORS {#ags312180-sec-0012}
=============================================================================================

Digestive cancers are tough targets for immunotherapy. ORR of PD‐1/PD‐L1 blockade were 17% for ESCC,[51](#ags312180-bib-0051){ref-type="ref"} 11.2% for GC,[52](#ags312180-bib-0052){ref-type="ref"}, [54](#ags312180-bib-0054){ref-type="ref"} 20% for HCC,[59](#ags312180-bib-0059){ref-type="ref"} and 0% for PDAC.[60](#ags312180-bib-0060){ref-type="ref"} dMMR tumors can be MSI‐H and show a somatic mutation frequency of more than 10‐100‐fold those of pMMR/microsatellite‐stable (MSS) tumors.[66](#ags312180-bib-0066){ref-type="ref"} Hence, dMMR/MSI‐H tumor is thought to have the potential to encode "non‐self" immunogenic antigens and is thought to respond well to immune checkpoint blockade. An interesting phase II study was evaluated for the clinical activity of pembrolizumab, an anti‐PD‐1 inhibitor. ORR was 40% for dMMR CRC, 71% for dMMR non‐CRC, and 0% for pMMR CRC.[55](#ags312180-bib-0055){ref-type="ref"} Blockade of PD‐1/PD‐L1 signaling brings durable efficacy for a subset of patients showing high tumor mutation burden (TMB) across almost all types of cancer, including many rare tumor types, characterized by dMMR/MSI‐H.[62](#ags312180-bib-0062){ref-type="ref"} The combination of nivolumab (PD‐1 blocker) plus ipilimumab (CTLA‐4 blocker) in dMMR/MSI‐H CRC was recently reported. Patients had an ORR of 55% and a DCR of 80%.[58](#ags312180-bib-0058){ref-type="ref"} However, not all patients with dMMR/MSI‐H achieved cure, even with the combination of immune checkpoint inhibitors, because of insufficient neoantigens, high tumor burden, suppressive immunity of the tumor microenvironment, or exhaustion of systemic immunosurveillance.[70](#ags312180-bib-0070){ref-type="ref"} These results clearly indicate that suppressive immunity should be controlled using a multidisciplinary approach (Table [5](#ags312180-tbl-0005){ref-type="table"}). PD‐L1 expression, CD8^+^ tumor‐infiltrating lymphocytes, and tumor mutation load are well‐known biomarkers of immune checkpoint inhibitors.[86](#ags312180-bib-0086){ref-type="ref"}, [87](#ags312180-bib-0087){ref-type="ref"}

###### 

List of suppressive immunity and its resolution methods

  Suppressive immunity                              Therapeutic strategies                                                          References
  ------------------------------------------------- ------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Treg                                              Cyclophosphamide, metformin                                                     [71](#ags312180-bib-0071){ref-type="ref"}, [72](#ags312180-bib-0072){ref-type="ref"}, [73](#ags312180-bib-0073){ref-type="ref"}, [74](#ags312180-bib-0074){ref-type="ref"}
  MDSC                                              COX2 inhibitors, cimetidine                                                     [71](#ags312180-bib-0071){ref-type="ref"}, [75](#ags312180-bib-0075){ref-type="ref"}, [76](#ags312180-bib-0076){ref-type="ref"}
  TIM‐3 expression on T cells (immune exhaustion)   Metformin, poly(I:C) plus LAG‐3‐Ig                                              [44](#ags312180-bib-0044){ref-type="ref"}, [77](#ags312180-bib-0077){ref-type="ref"}
  IL‐6                                              COX2 inhibitors, anti‐IL‐6 antibody                                             [78](#ags312180-bib-0078){ref-type="ref"}, [79](#ags312180-bib-0079){ref-type="ref"}
  TGF‐β                                             TGF‐β receptor inhibitor                                                        [80](#ags312180-bib-0080){ref-type="ref"}
  PGE2                                              COX2 inhibitors                                                                 [71](#ags312180-bib-0071){ref-type="ref"}, [81](#ags312180-bib-0081){ref-type="ref"}
  CAF                                               FAK inhibition                                                                  [82](#ags312180-bib-0082){ref-type="ref"}
  TAM                                               TGF‐β‐activated kinase‐1 inhibitor                                              [83](#ags312180-bib-0083){ref-type="ref"}
  Poor CTL infiltration                             Cetuximab, activate CD4^+^ lymphocytes, cancer antigen‐specific immunotherapy   [17](#ags312180-bib-0017){ref-type="ref"}, [46](#ags312180-bib-0046){ref-type="ref"}, [47](#ags312180-bib-0047){ref-type="ref"}, [48](#ags312180-bib-0048){ref-type="ref"}, [84](#ags312180-bib-0084){ref-type="ref"}
  PD‐1 expression on T cells                        PD‐1 blockade, poly(I:C) plus LAG‐3‐Ig                                          [44](#ags312180-bib-0044){ref-type="ref"}, [49](#ags312180-bib-0049){ref-type="ref"}
  PD‐L1 expression on tumor cells                   PD‐1/PD‐L1 blockade                                                             [49](#ags312180-bib-0049){ref-type="ref"}, [60](#ags312180-bib-0060){ref-type="ref"}
  IDO                                               IDO inhibitor                                                                   [85](#ags312180-bib-0085){ref-type="ref"}

CAF, cancer‐associated fibroblast; COX, cyclooxygenase; FAK, focal adhesion kinase; IDO, indoleamine‐2,3‐dioxygenase; Ig, immunoglobulin; IL‐6, interleukin‐6; LAG, lymphocyte activation gene; MDSC, myeloid‐derived suppressor cell; PD‐1, programmed cell death 1; PD‐L1, programmed cell death ligand 1; PGE2, prostaglandin E2; TAM, tumor‐associated macrophage; TGF, transforming growth factor; TIM‐3, T‐cell immunoglobulin and mucin domain‐containing protein‐3; Treg, regulatory T cell.

John Wiley & Sons, Ltd

Recent immune checkpoint blockade therapy has basically shown two mechanisms of immunosuppression. First, through the production of secreted suppressive molecules such as transforming growth factor (TGF)‐β, IL‐6, and prostaglandin E2 (PGE2) and, second, through various immunosuppressive cells such as regulatory T cells (Treg), myeloid‐derived suppressor cells (MDSC), tumor‐associated macrophages (TAM), and cancer‐associated fibroblasts (CAF), which are partly induced by the secreted factors mentioned above (Figure [1](#ags312180-fig-0001){ref-type="fig"}A‐C). These molecules and cells are supplied to lymph nodes where anti‐tumor T cells are induced and are subsequently immunologically suppressed in patients with cancer (Figure [1](#ags312180-fig-0001){ref-type="fig"}D,E).[8](#ags312180-bib-0008){ref-type="ref"}

![Concept of immunological status of various tumors or patients and implications for immunotherapy. A, Hot tumor might respond well to immune checkpoint inhibitors. B, Dark tumor might need immune checkpoint inhibitors and agents to resolve suppressive immunity. C, Cold tumor might require combination therapies comprising an agent to create an immunogenic tumor microenvironment plus immune checkpoint inhibitors and agents to resolve suppressive immunity. D, Patients without immune exhaustion might not need additional treatment. E, Patients with immune exhaustion might need additional treatment to resolve exhaustion. CAF, cancer‐associated fibroblasts; CRP, C‐reactive protein; IDO, indoleamine‐2,3‐dioxygenase; IL, interleukin; MDSC, myeloid‐derived suppressor cells; NLR, neutrophil‐to‐lymphocyte ratio; PD‐1, programmed cell death 1; PD‐L1, programmed death ligand 1; PGE2, prostaglandin E2; TAM, tumor‐associated macrophage; TGF‐β, transforming growth factor beta; TIM‐3, T‐cell immunoglobulin and mucin domain‐containing protein‐3; Treg, regulatory T cell](AGS3-2-289-g001){#ags312180-fig-0001}

One way to achieve successful immunotherapies is to establish biomarkers for excluding those patients unlikely to respond to immunotherapy (Figure [1](#ags312180-fig-0001){ref-type="fig"}E). The old‐new biomarker is NLR, which is prognostic in many oncological settings. NLR kinetics in patients with advanced solid tumors treated with PD‐1/PD‐L1 inhibitors showed that the median OS for patients with a high NLR was 8.5 months, compared to 19.4 for patients with low NLR (*P* = .01).[88](#ags312180-bib-0088){ref-type="ref"} The importance of NLR was also reported in a study of a peptide vaccine against CRC.[17](#ags312180-bib-0017){ref-type="ref"} Circulating CD8^+^ T cells are incontrovertibly important. Huang et al[70](#ags312180-bib-0070){ref-type="ref"} reported that the T‐cell invigoration‐to‐tumor burden ratio was associated with anti‐PD‐1 response, and T‐cell invigoration could be monitored as low expression of Ki‐67 on circulating CD8 T cells. To alter the T‐cell invigoration‐to‐tumor burden ratio, chemotherapy or radiation might be useful strategies in combination with immune checkpoint inhibitors, and numerous phase studies of such combination therapy are ongoing.

Another way to achieve successful immunotherapies is to alter tumor microenvironments and host immunosurveillance. So‐called "hot tumor" with massive infiltration of CD8^+^ cells and without suppressive immunity could respond well to immune checkpoint inhibitor alone (Figure [1](#ags312180-fig-0001){ref-type="fig"}A,D). Each of "dark tumor" (Figure [1](#ags312180-fig-0001){ref-type="fig"}B), which is highly immunogenic but with suppressive immunity, "cold tumor" (Figure [1](#ags312180-fig-0001){ref-type="fig"}C), which shows low immunogenicity with suppressive immunity, and patients with immune exhaustion (Figure [1](#ags312180-fig-0001){ref-type="fig"}E) might require a multidisciplinary approach (Table [5](#ags312180-tbl-0005){ref-type="table"}).

The immunosuppressive environment surrounding PDAC might be one of the major obstacles to the development of successful therapies for this fatal disease.[69](#ags312180-bib-0069){ref-type="ref"} Advances in our understanding of the immunosuppressive mechanisms in PDAC might lead to promising immunotherapeutic approaches. PDAC patients displayed an increased number of Treg and MDSC.[71](#ags312180-bib-0071){ref-type="ref"} Cyclophosphamide[72](#ags312180-bib-0072){ref-type="ref"} and metformin[73](#ags312180-bib-0073){ref-type="ref"} could downregulate the number and function of Treg, and cyclooxygenase (COX)‐2 inhibitors[75](#ags312180-bib-0075){ref-type="ref"} and cimetidine[76](#ags312180-bib-0076){ref-type="ref"} could regulate MDSC. Metformin is also reported to have a direct effect on CD8^+^ T cells for protection against the inevitable functional exhaustion marker T‐cell immunoglobulin and mucin domain‐containing protein‐3 (Tim‐3) in the tumor microenvironment.[77](#ags312180-bib-0077){ref-type="ref"} The production of secreted suppressive molecules such as IL‐6 leads to the limited efficacy of immune checkpoint inhibitors in PDAC, so IL‐6 blockade would modulate the immunological features of PDAC. An experimental study of combined IL‐6 and PD‐L1 blockade elicited efficacy in mice bearing s.c. tumors, accompanied by increased intratumoral effector T lymphocytes. These preclinical results indicate that targeted inhibition of IL‐6 may enhance the efficacy of anti‐PD‐L1 in PDAC (Table [5](#ags312180-tbl-0005){ref-type="table"}).[78](#ags312180-bib-0078){ref-type="ref"} Other inhibitory factors in the tumor microenvironment, such as TGF‐β[80](#ags312180-bib-0080){ref-type="ref"} and PGE2[75](#ags312180-bib-0075){ref-type="ref"}, [81](#ags312180-bib-0081){ref-type="ref"} and its inhibitors, are summarized in Table [5](#ags312180-tbl-0005){ref-type="table"}.

Another problem is the presence of a uniquely desmoplastic stroma that functions as a barrier to T‐cell infiltration (Figure [1](#ags312180-fig-0001){ref-type="fig"}B,C). Hyperactivated focal adhesion kinase (FAK) activity in PDAC cells is an important regulator of the fibrotic and immunosuppressive microenvironments. FAK activity is elevated in human PDAC tissues and correlates with high levels of fibrosis and poor CD8^+^ cytotoxic T‐cell infiltration.[82](#ags312180-bib-0082){ref-type="ref"} Single‐agent FAK inhibition using the selective FAK inhibitor VS‐4718 substantially limited tumor progression, resulting in a doubling of survival in a mouse model of human PDAC. This delay in tumor progression was associated with markedly reduced CAF and decreased numbers of tumor‐infiltrating immunosuppressive cells.[82](#ags312180-bib-0082){ref-type="ref"} TAM[83](#ags312180-bib-0083){ref-type="ref"} are also an inhibitory factor in tumor microenvironments, and associated therapeutic strategies are shown in Table [5](#ags312180-tbl-0005){ref-type="table"}.

Tumor tissues that lack expression of many immunological markers may indicate a non‐immunogenic tumor microenvironment (Figure [1](#ags312180-fig-0001){ref-type="fig"}C), which may require combination therapies consisting of an agent to create an immunogenic tumor microenvironment plus an immune checkpoint agent to further enhance immune responses for clinical benefit.[86](#ags312180-bib-0086){ref-type="ref"} Conventional cancer therapies such as chemotherapy or radiation may also lead to tumor cell death and release of antigens to initiate activation of T cells, which may then migrate into tumor tissues. Combination studies using conventional agents and immune checkpoint therapies should thus clarify the conditions needed to create an "immunogenic" tumor microenvironment with subsequent clinical benefit for patients.[86](#ags312180-bib-0086){ref-type="ref"} We have reported that cetuximab strongly enhances immune cell infiltration into liver metastatic sites in CRC.[46](#ags312180-bib-0046){ref-type="ref"} Cetuximab induces antibody‐dependent cell‐mediated cytotoxicity and immunogenic cell death. We assessed immune cell infiltration into liver metastatic sites of 53 CRC patients treated with chemotherapy and cetuximab, chemotherapy without cetuximab, and no chemotherapy. Of note, inflammatory cells were found in intratumoral areas, and the destruction of cancer cell foci was observed in the cetuximab group. Moreover, higher infiltration of CD8^+^ (*P* = .003) and CD56^+^ (*P* = .001) cells was observed in the cetuximab group. The immune‐related mechanism of cetuximab may enhance the efficacy of combination therapy using immune checkpoint inhibitors and/or therapeutic peptides.[46](#ags312180-bib-0046){ref-type="ref"}

Although no objective responder to pembrolizumab is seen in pMMR/MSS‐CRC, some patients obtained SD lasting more than 3 months according to tumor markers as well as radiographical evaluation,[55](#ags312180-bib-0055){ref-type="ref"} indicating that some groups of MSS‐CRC could respond to PD‐1 blockade. Galon et al[89](#ags312180-bib-0089){ref-type="ref"} attested that MSS colon cancer is divided into tumors with or without massive CD8^+^ T‐cell infiltration. The reason why metastatic MSS‐CRC did not respond well to immune checkpoint inhibitors might be divided into two patterns, owing to the highly immunosuppressive state of the "dark tumor" microenvironment (Figure [1](#ags312180-fig-0001){ref-type="fig"}B) and the low immunogenicity in the "cold tumor" microenvironment (Figure [1](#ags312180-fig-0001){ref-type="fig"}C). For dark tumors, a combination of immune checkpoint inhibitors and the modalities summarized in Table [5](#ags312180-tbl-0005){ref-type="table"} to resolve the suppressive immunity might prove effective. For cold tumors (Figure [1](#ags312180-fig-0001){ref-type="fig"}C), additional use of methods to induce immune cells to the tumor site would be needed, as described above. The combination of neoantigen‐derived vaccination and cetuximab might be one of the most promising strategies.

Hence, combination immunotherapy should be selected as a precision medicine based on comprehensive analyses using whole‐exome sequencing and RNA sequences. Moreover, novel immune checkpoints might not yet have been detected. Absolutely effective combination strategies might be just around the corner.
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